COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab

Nephrol Dial Transplant. 2021 Aug 27;36(9):1758-1760. doi: 10.1093/ndt/gfab174.
No abstract available

MeSH terms

  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / drug therapy
  • Antibodies, Antineutrophil Cytoplasmic
  • COVID-19 Vaccines*
  • COVID-19* / prevention & control
  • Humans
  • Immunologic Factors
  • Remission Induction
  • Rituximab / therapeutic use*

Substances

  • Antibodies, Antineutrophil Cytoplasmic
  • COVID-19 Vaccines
  • Immunologic Factors
  • Rituximab